Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today ...

Relmada Therapeutics’ attempts to see whether a magic mushroom extract could be used to treat obesity and metabolic diseases may be coming to an end before they really began. The biotech launched a ...

Month Phase 2 data in High-Risk NMIBC to be presented Friday, May 15, 2026Phase 3 overview to be presented at Trials-in-Progress session on ...

Relmada Therapeutics’ lead asset flunked a phase 3 trial in major depressive disorder (MDD), plunging the biotech’s stock 77%. The Reliance III trial saw 232 participants receive the therapy, dubbed ...

The 12-month interim data from the ongoing Phase 2 trial showed a complete response rate of 76%, with an impressive 80% in the BCG-unresponsive patient population. On Monday, the trial showed a ...

On Wednesday, Relmada Therapeutics, Inc. (NASDAQ:RLMD) announced a preplanned interim analysis of the Reliance II Phase 3 study. Reliance II is designed to evaluate REL-1017 as an adjunctive treatment ...

Relmada Therapeutics Inc (RLMD) showcases robust clinical data and strategic financial moves, despite facing increased expenses and net loss.

View Relmada Therapeutics Inc RLMD stock quote prices, financial information, real-time forecasts, and company news from CNN.

Q1 2026 Management View "Relmada continues to make excellent progress this year, and we are excited about where we stand," ...

Unlock your investing potential with TipRanks Premium - Now At 40% OFF! Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter Relmada Therapeutics ( (RLMD)) just ...

Image source: The Motley Fool. Relmada Therapeutics (NASDAQ:RLMD) reported that clinical progress for NDV01 includes durable, high 12-month complete response rates in both broad and BCG-unresponsive ...

CORAL GABLES, Fla., May 06, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for ...